看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 7.0x - 7.7x | 7.3x |
| Selected Fwd P/E Multiple | 32.9x - 36.3x | 34.6x |
| Fair Value | $16.28 - $17.99 | $17.14 |
| Upside | 28.9% - 42.5% | 35.7% |
| Benchmarks | - | Full Ticker |
| MiMedx Group, Inc. | - | NasdaqCM:MDXG |
| 4Front Ventures Corp. | - | OTCPK:FFNT.F |
| Evolus, Inc. | - | NasdaqGM:EOLS |
| Tarsus Pharmaceuticals, Inc. | - | NasdaqGS:TARS |
| Bio Essence Corporation | - | OTCPK:BIOE |
| BioStem Technologies, Inc. | - | OTCPK:BSEM |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| MDXG | FFNT.F | EOLS | TARS | BIOE | BSEM | |||
| NasdaqCM:MDXG | OTCPK:FFNT.F | NasdaqGM:EOLS | NasdaqGS:TARS | OTCPK:BIOE | OTCPK:BSEM | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | -41.6% | 31.3% | 6.3% | 29.2% | -287.0% | 475.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -1.2% | -170.4% | -83.6% | -262.7% | -170.1% | -77.2% | ||
| Prior Fiscal Year | 17.4% | -19.8% | -30.5% | -778.9% | NA | -50.8% | ||
| Latest Fiscal Year | 12.0% | -45.9% | -18.9% | -63.2% | -483.3% | 10.6% | ||
| Latest Twelve Months | 11.3% | -46.6% | -20.4% | -44.9% | -483.3% | 10.6% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 15.7x | -13.2x | -25.7x | -14.1x | -23.5x | 7.5x | ||
| Price / LTM Sales | 3.0x | 0.0x | 2.3x | 7.9x | 24.9x | 0.8x | ||
| LTM P/E Ratio | 26.8x | -0.1x | -11.4x | -17.7x | -5.1x | 8.0x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -17.7x | -5.1x | 26.8x | |||||
| Historical LTM P/E Ratio | -9.3x | -8.1x | 8.0x | |||||
| Selected P/E Multiple | 7.0x | 7.3x | 7.7x | |||||
| (x) LTM Net Income | 32 | 32 | 32 | |||||
| (=) Equity Value | 222 | 234 | 246 | |||||
| (/) Shares Outstanding | 16.7 | 16.7 | 16.7 | |||||
| Implied Value Range | 13.30 | 14.00 | 14.70 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 13.30 | 14.00 | 14.70 | 12.63 | ||||
| Upside / (Downside) | 5.3% | 10.8% | 16.4% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | MDXG | FFNT.F | EOLS | TARS | BIOE | BSEM | |
| Value of Common Equity | 1,059 | 3 | 653 | 1,742 | 8 | 211 | |
| (/) Shares Outstanding | 147.7 | 916.4 | 64.5 | 42.0 | 38.0 | 16.7 | |
| Implied Stock Price | 7.17 | 0.00 | 10.13 | 41.46 | 0.21 | 12.63 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 7.17 | 0.00 | 10.13 | 41.46 | 0.21 | 12.63 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |